Replies to post #448942 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Good post, jt. If Anavex had any concerns with 2-73, we'd be seeing 3-71 starting Rett or AD trials, not schizophrenia.
It's clear that 3-71 has favorable M1 activation, in addition to S1R, to make it more optimal for schizophrenia therapy.
Though, it's very likely we'll see a future AD P3 trial with 3-71, only after 2-73 has been approved and producing large revenue.
Building out the value proposition with two drugs.